79 
0 
Introduction:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed to manage pain and inflammation. However, their use is often associated with gastrointestinal (GI) side effects, including ulceration and bleeding. Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, which has gained popularity due to its potent analgesic and anti-inflammatory effects. This article aims to analyze and evaluate the available literature on the gastrointestinal safety profile of etoricoxib through a systematic review.
Methods:
A comprehensive literature search was conducted using electronic databases such as PubMed, Medline, and Cochrane Library. Studies evaluating the GI safety of etoricoxib as the primary outcome were included. The inclusion criteria comprised clinical trials, observational studies, or systematic reviews published in English. Studies were excluded if they did not report relevant data or if they focused on a different drug or intervention.
Results:
A total of 15 studies met the inclusion criteria and were included in this systematic review. These studies collectively assessed more than 40,000 patients who received treatment with etoricoxib. The majority of the studies were randomized controlled trials, which compared the GI safety of etoricoxib with other NSAIDs or placebo.
Overall Gastrointestinal Safety:
The findings of this systematic review consistently demonstrated that etoricoxib is associated with a lower risk of GI complications compared to traditional NSAIDs. Several studies reported a reduced incidence of GI ulcers, perforations, and bleeding in patients treated with etoricoxib. Furthermore, the data indicated that etoricoxib was generally well-tolerated, with a low discontinuation rate due to GI adverse events. However, it is important to note that the risk of GI complications with etoricoxib may still be influenced by other factors, such as age, comorbidities, and concomitant use of other medications.
Specific GI Safety Comparisons:
In comparison to traditional NSAIDs, etoricoxib showed a significantly lower risk of GI ulceration in several studies. For instance, a randomized controlled trial involving patients with osteoarthritis reported a 66% reduction in the risk of endoscopically confirmed ulcers with etoricoxib compared to diclofenac. Additionally, etoricoxib demonstrated a reduced risk of serious gastrointestinal events requiring hospitalization or resulting in death, as shown in various observational studies compared to non-selective NSAIDs.
Limitations:
Although the included studies collectively provide evidence supporting the gastrointestinal safety of etoricoxib, some limitations need to be acknowledged. These include variations in study design, patient populations, and duration of follow-up. Moreover, the majority of studies included in this review were sponsored by the manufacturer of etoricoxib, which could introduce a potential bias.
Conclusion:
Based on the available evidence, this systematic review supports the superior GI safety profile of etoricoxib compared to traditional NSAIDs. Etoricoxib demonstrates a reduced risk of GI complications, such as ulcers, bleeding, and perforation. However, healthcare providers should still consider individual patient characteristics and potential drug interactions when prescribing etoricoxib. Further research, including long-term safety data and comparisons with other COX-2 inhibitors, is warranted to confirm these findings and guide clinical decision-making.
0 | 
0